ClinVar Miner

Submissions for variant NM_001999.4(FBN2):c.8701G>A (p.Glu2901Lys)

gnomAD frequency: 0.00003  dbSNP: rs781069799
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000197656 SCV000250262 uncertain significance not provided 2013-07-10 criteria provided, single submitter clinical testing p.Glu2901Lys (GAG>AAG): c.8701 G>A in exon 65 of the FBN2 gene (NM_001999.3) The Glu2901Lys variant in the FBN2 gene has not been reported as a disease-causing mutation or as a benign polymorphism to our knowledge. Glu2901Lys results in a non-conservative amino acid substitution of a negatively charged Glutamic acid with a positively charged Lysine at a position that is conserved in mammals. Nevertheless, no mutations in nearby residues have been reported in association with contractural arachnodactyly. Data from control individuals were not available to assess whether Glu2901Lys may be a common benign variant in the general population. With the clinical and molecular information available at this time, we cannot definitively determine if Glu2901Lys is a disease-causing mutation or a rare benign variant. This variant was found in TAAD
Invitae RCV001241938 SCV001414993 likely benign Congenital contractural arachnodactyly 2022-06-28 criteria provided, single submitter clinical testing
Ambry Genetics RCV002372170 SCV002684611 uncertain significance Familial thoracic aortic aneurysm and aortic dissection 2018-12-06 criteria provided, single submitter clinical testing The p.E2901K variant (also known as c.8701G>A), located in coding exon 65 of the FBN2 gene, results from a G to A substitution at nucleotide position 8701. The glutamic acid at codon 2901 is replaced by lysine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.